🔎 Trials Near Me

Inicio › Colitis ulcerativa › Maryland

Ensayos clínicos de Colitis ulcerativa en Maryland

13 estudios sobre Colitis ulcerativa buscan participantes en Maryland.

Ciudades en Maryland

Texto oficial del estudio (inglés)

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

  • National Institutes of Health Clinical Center, Bethesda
ReclutandoEstudio observacional
Edades de 18 a 85 · Todos los sexos · Actualizado el 29 sept 2026 · NCT07619547

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  • Site 011, Glen Burnie
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 29 sept 2026 · NCT07012395

Immune Regulation in Ulcerative Colitis or Crohn s Disease

  • National Institutes of Health Clinical Center, Bethesda
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
1 Day – 75 Years · Todos los sexos · Actualizado el 28 sept 2026 · NCT00001184

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  • Chevy Chase Clinical Research, Chevy Chase
  • Woodholme Gastroenterology Associates, Glen Burnie
ReclutandoFase 3
Edades de 12 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07196748

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Capital Digestive Care - Chevy Chase, Chevy Chase
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06937086

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • National Cancer Institute Developmental Therapeutics Clinic, Bethesda
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT03816345

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  • Capital Digestive Care - MGG Group - Chevy Chase Clinical Research, Chevy Chase
ReclutandoFase 4
Edades de 18 a 65 · Todos los sexos · Actualizado el 21 sept 2026 · NCT06095128

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Capital Digestive Care, Chevy Chase
  • Woodholme Gastroenterology, Glen Burnie
ReclutandoFase 4
Edades de 18 a 80 · Todos los sexos · Actualizado el 15 sept 2026 · NCT06581328

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • Mercy Medical Center, Baltimore - Site Number: 8400117, Baltimore
  • Mid-Atlantic GI Research, LLC - Site Number: 8400106, Greenbelt
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 20 ago 2026 · NCT07184996

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • Mercy Medical Center, Baltimore
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT07237516

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

  • MGG Group Co., Inc., Chevy Chase Clinical Research, Chevy Chase
  • Woodholme Gastroenterology Associates PA, Glen Burnie
ReclutandoEstudio observacional
Edades de 18 a 64 · Todos los sexos · Actualizado el 9 jul 2026 · NCT06398626

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  • Woodholme Gastroenterology Associates, Glen Burnie
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 22 may 2026 · NCT06764615

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

  • Capital Digestive Care, Chevy Chase
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 may 2025 · NCT06750731

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.